CymaBay Therapeutics (CBAY) Appoints Eric Lefebvre to its Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to CymaBay Therapeutics (CBAY) Appoints Eric Lefebvre to its Board

CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors

March 17, 2022 4:25 PM EDT

NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to its Board of Directors.

We are excited to be welcoming Éric to the Board. Érics extensive experience in the pharmaceutical industry as an executive focused on clinical development, medical affairs, business development and life-cycle strategy and more than 10 years of experience developing drugs in liver disease indications... More